Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.

PHASE3CompletedINTERVENTIONAL

Enrollment

129

Participants

Timeline

Start Date

November 6, 2019

Primary Completion Date

February 22, 2023

Study Completion Date

February 22, 2023

Conditions

Chemotherapy-Induced Thrombocytopenia

Interventions

DRUG

Hetrombopag

DRUG

Placebo

Trial Locations (1)

Najing Bayi Hospital, Nanjing

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03976882 - Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy. | Biotech Hunter | Biotech Hunter